Author: super@dmin
-
Dow Jones Newswires: Roche’s phase 3 data show Lymphoma treatment can reduce disease risks
Polivy is currently marketed in the European Union for the treatment of relapsed or refractory diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
-
The Wall Street Journal: Amgen reportedly in talks to buy Horizon Therapeutics
The U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal.
-
The Wall Street Journal: Ukraine hits hotel housing Russian military members
Footage of the Ukrainian artillery strike against a hotel in the Russian-occupied city of Melitopol showed dead and wounded Russian soldiers
-
The Wall Street Journal: Congress spends last days before new session on spending bill to avoid government shutdown
Negotiators are hoping to reach a deal on a full-year spending bill but they disagree on nondefense spending
-
Financial Face-Off: Financial Face-off: Should you opt for a high-deductible health plan with lower monthly costs?
It’s open-enrollment season: Here’s what to know if you’re considering a high-deductible health plan.
-
Earnings Watch: One company could determine if U.S. corporate profits rise to a record next year
As Wall Street starts to look toward 2023, earnings growth for the companies that make up the S&P 500 index could hinge just on one: Amazon.
-
Front Office Sports: Grant Wahl’s death of ‘cardiac arrest’ at World Cup casts pall over tournament
Medics on the scene described Grant Wahl’s death as related to cardiac arrest while covering a World Cup quarterfinal contest.
-
: Elon Musk’s Twitter to bring back subscription program ‘Twitter Blue’ Monday
Twitter plans to restart its Twitter Blue subscription program Monday with new rules and, in one case, a new price.
-
: Want a cooler Twitter handle? You may soon get the chance to snag a status symbol.
Elon Musk says Twitter plans to release dormant account names.
-
Earnings Outlook: Oracle may be hit by same ‘softening macro trends’ affecting other software firms, analyst says
Oracle’s stock has fallen 9.5% so far this year.